Table 5.
Distribution of CVD types in the context of SARS-Cov-2 test and sex.
| Overall distribution (regardless of sex, N = 2003) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | Class | SARS-Cov-2: negative | SARS-Cov-2: positive | SARS-Cov-2: negative | SARS-Cov-2: positive | No stratification corrections | Generalized CMH (adjusted for stratification by sex) | ||||||||
| Count (n) | Count (n) | Frequency (%) | Frequency (%) | χ2 | p | OR | OR {− 95% CI} | OR {95% CI} | χ2 | p | OR | OR {− 95% CI} | OR {95% CI} | ||
| ACS | ACS | 815 (805.0) | 69 (79.0) | 44.68 | 38.55 | 2.49 | 0.1147 | – | – | – | 3.17 | 0.0750 | – | – | – |
| No ACS | 1009 (1019.0) | 110 (100.0) | 55.32 | 61.45 | |||||||||||
| Arrhythmia | Arrhythmia | 327 (322.36) | 27 (31.64) | 17.93 | 15.08 | 0.91 | 0.3412 | – | – | – | 0.68 | 0.4062 | – | – | – |
| No arrhythmia | 1497 (1501.64) | 152 (147.36) | 82.07 | 84.92 | |||||||||||
| PE | PE | 28 (36.43) | 12 (3.57) | 1.54 | 6.70 | 22.25 | < 0.00001 | 4.609 | 2.301 | 9.231 | 23.33 | < 0.00001 | 4.772 | 2.377 | 9.579 |
| No PE | 1796 (1787.57) | 167 (175.43) | 98.46 | 93.30 | |||||||||||
| AHF | AHF | 155 (158.45) | 19 (15.55) | 8.50 | 10.61 | 0.92 | 0.3373 | – | – | – | 0.94 | 0.3330 | – | – | – |
| No AHF | 1669 (1665.55) | 160 (163.45) | 91.50 | 89.39 | |||||||||||
| Other CVDs | Other CVDs | 499 (501.76) | 52 (49.24) | 27.36 | 29.05 | 0.23 | 0.6284 | – | – | – | 0.32 | 0.5703 | – | – | – |
| ACS/arrhythmia/PE/AHF | 1325 (1322.24) | 127 (129.76) | 72.64 | 70.95 | |||||||||||
| Subset distribution (sex: female, N = 767) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | Class | SARS-Cov-2: negative | SARS-Cov-2: positive | SARS-Cov-2: negative | SARS-Cov-2: positive | χ2 | p | OR | OR {-95% CI} | OR {95% CI} | |||||
| Count (n) | Count (n) | Frequency (%) | Frequency (%) | ||||||||||||
| ACS | ACS | 263 (256.62) | 15 (21.38) | 37.15 | 25.42 | 3.24 | 0.0719 | – | – | – | |||||
| No ACS | 445 (451.38) | 44 (37.62) | 62.85 | 74.58 | |||||||||||
| Arrhythmia | Arrhythmia | 154 (154.15) | 13 (12.85) | 21.75 | 22.03 | 0.0026 | 0.9597 | – | – | – | |||||
| No arrhythmia | 554 (553.85) | 46 (46.15) | 78.25 | 77.97 | |||||||||||
| PE | PE | 14 (18.46) | 6 (1.54) | 1.98 | 10.17 | 14.39 | 0.0002 | 5.612 | 2.072 | 15.199 | |||||
| No PE | 694 (689.54) | 53 (57.46) | 98.02 | 89.83 | |||||||||||
| AHF | AHF | 58 (62.77) | 10 (5.23) | 8.19 | 16.95 | 5.17 | 0.0230 | 2.287 | 1.101 | 4.752 | |||||
| No AHF | 650 (645.23) | 49 (53.77) | 91.81 | 83.05 | |||||||||||
| Other CVDs | Other CVDs | 219 (216.0) | 15 (18.0) | 30.93 | 25.42 | 0.78 | 0.3773 | – | – | – | |||||
| ACS/arrhythmia/PE/AHF | 489 (492.0) | 44 (41.0) | 69.07 | 74.58 | |||||||||||
| Subset distribution (sex: male, N = 1236) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | Class | SARS-Cov-2: negative | SARS-Cov-2: positive | SARS-Cov-2: negative | SARS-Cov-2: positive | χ2 | p | OR | OR {− 95% CI} | OR {95% CI} | |||||
| Count (n) | Count (n) | Frequency (%) | Frequency (%) | ||||||||||||
| ACS | ACS | 552 (547.17) | 54 (58.83) | 49.46 | 45.00 | 0.86 | 0.3528 | – | – | – | |||||
| No ACS | 564 (568.83) | 66 (61.17) | 50.54 | 55.00 | |||||||||||
| Arrhythmia | Arrhythmia | 173 (168.84) | 14 (18.16) | 15.50 | 11.67 | 1.24 | 0.2653 | – | – | – | |||||
| No arrhythmia | 943 (947.16) | 106 (101.84) | 84.50 | 88.33 | |||||||||||
| PE | PE | 14 (18.06) | 6 (1.94) | 1.25 | 5.00 | 9.55 | 0.0020 | 4.143 | 1.562 | 10.990 | |||||
| No PE | 1102 (1097.94) | 114 (118.06) | 98.75 | 95.00 | |||||||||||
| AHF | AHF | 97 (95.71) | 9 (10.29) | 8.69 | 7.50 | 0.20 | 0.6578 | – | – | – | |||||
| No AHF | 1019 (1020.29) | 111 (109.71) | 91.31 | 92.50 | |||||||||||
| Other CVDs | Other CVDs | 280 (286.22) | 37 (30.78) | 25.09 | 30.83 | 1.87 | 0.1710 | – | – | – | |||||
| ACS/arrhythmia/PE/AHF | 836 (829.78) | 83 (89.22) | 74.91 | 69.17 | |||||||||||
Numbers in ‘()’ brackets indicate expected (estimated) counts. Significant odds ratios (ORs) are marked in bold.